MX2020008902A - Analogos de compstatina y sus usos medicos. - Google Patents

Analogos de compstatina y sus usos medicos.

Info

Publication number
MX2020008902A
MX2020008902A MX2020008902A MX2020008902A MX2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A MX 2020008902 A MX2020008902 A MX 2020008902A
Authority
MX
Mexico
Prior art keywords
compstatin
analogues
introduction
complement
inhibiting activity
Prior art date
Application number
MX2020008902A
Other languages
English (en)
Inventor
Pernille Tofteng Shelton
Jacob Ulrik Fog
Jens Kvist Madsen
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of MX2020008902A publication Critical patent/MX2020008902A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen análogos de compstatina que tienen unión y actividad de inhibición del complemento mejoradas en comparación con el péptido de compstatina de 13 aminoácidos (ICVVQDWGHHRCT (C2-C12 cíclico)), en particular análogos de compstatina que adicionalmente poseen propiedades fisicoquímicas útiles, tales como aumento de solubilidad. Estos análogos incluyen variantes con un residuo de isoleucina en la posición 3 en lugar del residuo de valina de tipo natural, que proporciona péptidos de compstatina con unión y actividad de inhibición del complemento mejoradas y también permite la introducción de otras modificaciones, por ejemplo, modificaciones que son capaces de aumentar la solubilidad, tal como la introducción de aminoácidos cargados o polares en la posición 9 y/o la introducción de secuencias de N- y/o C-terminales.
MX2020008902A 2018-02-27 2019-02-26 Analogos de compstatina y sus usos medicos. MX2020008902A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18158834 2018-02-27
EP18214949 2018-12-20
PCT/EP2019/054685 WO2019166411A1 (en) 2018-02-27 2019-02-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
MX2020008902A true MX2020008902A (es) 2020-12-03

Family

ID=65516661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008902A MX2020008902A (es) 2018-02-27 2019-02-26 Analogos de compstatina y sus usos medicos.

Country Status (17)

Country Link
US (2) US11965039B2 (es)
EP (1) EP3759120A1 (es)
JP (1) JP2021515759A (es)
KR (1) KR20200135797A (es)
CN (1) CN112041330A (es)
AU (1) AU2019228639A1 (es)
BR (1) BR112020017385A2 (es)
CA (1) CA3091993A1 (es)
CL (1) CL2020002197A1 (es)
CO (1) CO2020011027A2 (es)
IL (1) IL276877A (es)
MX (1) MX2020008902A (es)
PE (1) PE20201254A1 (es)
RU (1) RU2020128624A (es)
SG (1) SG11202008177WA (es)
TW (1) TW202000686A (es)
WO (1) WO2019166411A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057693T2 (hu) 2018-04-06 2022-05-28 Univ Pennsylvania Fokozott oldhatóságú és javított farmakokinetikai tulajdonságú kompsztatin analógok
US20220306695A1 (en) * 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
CA3185730A1 (en) * 2020-07-16 2022-01-20 Anne Pernille Tofteng SHELTON Inhibitors of complement factor c3 and their medical uses
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2024110878A1 (en) * 2022-11-24 2024-05-30 Amyndas Pharmaceuticals Us Llc Compstatin analogs for vector-based therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0894002A4 (en) 1996-03-13 2001-11-14 Univ Pennsylvania NEW PEPTIDES INHIBITING SUPPLEMENT ACTIVATION
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999013899A1 (en) * 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CN1344248A (zh) 1999-03-17 2002-04-10 诺沃挪第克公司 肽的酰化方法和新酰化剂
EP2311479B1 (en) 2002-09-20 2014-07-23 The Trustees of The University of Pennsylvania Compstatin analogs with improved activity
PL1951279T3 (pl) 2005-10-08 2017-12-29 Apellis Pharmaceuticals, Inc. Kompstatyna i jej analogi w zaburzeniach oczu
RU2474586C2 (ru) * 2005-11-28 2013-02-10 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Эффективные аналоги компстатина
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
HUE035378T2 (en) 2009-05-01 2018-05-02 Univ Pennsylvania Compstatin with peptide framework and C-terminal modifications
US20140113874A1 (en) * 2010-09-23 2014-04-24 The Trustees Of The University Of Pennsylvania Modified Compstatin With Improved Stability And Binding Properties
DK2753636T3 (da) * 2011-09-07 2020-02-03 Univ Pennsylvania Compstatinanaloger med forbedret farmakokinetiske egenskaber
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US9512180B2 (en) * 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
US20220306695A1 (en) * 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
US20240309046A1 (en) 2024-09-19
EP3759120A1 (en) 2021-01-06
CL2020002197A1 (es) 2021-03-05
JP2021515759A (ja) 2021-06-24
RU2020128624A (ru) 2022-03-28
TW202000686A (zh) 2020-01-01
CN112041330A (zh) 2020-12-04
CA3091993A1 (en) 2019-09-06
SG11202008177WA (en) 2020-09-29
CO2020011027A2 (es) 2020-12-10
AU2019228639A1 (en) 2020-09-17
WO2019166411A1 (en) 2019-09-06
KR20200135797A (ko) 2020-12-03
IL276877A (en) 2020-10-29
US11965039B2 (en) 2024-04-23
US20230192770A1 (en) 2023-06-22
PE20201254A1 (es) 2020-11-16
BR112020017385A2 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
MX2022002433A (es) Análogos de compstatina y sus usos médicos.
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
EA201691111A1 (ru) Химерные белки фактора viii и их применение
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
EP4011905A3 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
MX2023000679A (es) Inhibidores del factor c3 del complemento y sus usos medicos.
BR112022012057A2 (pt) Novos métodos de entrega celular
WO2015110809A3 (en) Drug delivery system
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
MX2010005816A (es) Epítopos de péptido de stat3.
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
WO2019059572A3 (ko) 홍어 껍질 유래의 신규한 항균 펩타이드 및 이의 용도
EP4403566A3 (en) Peptides with vasodilatory and/or diuretic functions
PH12021551150A1 (en) Transmembrane domain derived from human lrrc24 protein